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ARTICLE
Role of cyclooxygenase-2-mediated prostaglandin
E2-prostaglandin E receptor 4 signaling in cardiac
reprogramming
Naoto Muraoka1, Kaori Nara1, Fumiya Tamura1, Hidenori Kojima1, Hiroyuki Yamakawa1, Taketaro Sadahiro2,
Kazutaka Miyamoto1, Mari Isomi2, Sho Haginiwa1, Hidenori Tani1, Shota Kurotsu1, Rina Osakabe1, Satoru Torii3,
Shigeomi Shimizu3, Hideyuki Okano4, Yukihiko Sugimoto 5, Keiichi Fukuda 1 & Masaki Ieda2
Direct cardiac reprogramming from ﬁbroblasts can be a promising approach for disease
modeling, drug screening, and cardiac regeneration in pediatric and adult patients. However,
postnatal and adult ﬁbroblasts are less efﬁcient for reprogramming compared with embryonic
ﬁbroblasts, and barriers to cardiac reprogramming associated with aging remain unde-
termined. In this study, we screened 8400 chemical compounds and found that diclofenac
sodium (diclofenac), a non-steroidal anti-inﬂammatory drug, greatly enhanced cardiac
reprogramming in combination with Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Hand2.
Intriguingly, diclofenac promoted cardiac reprogramming in mouse postnatal and adult tail-tip
ﬁbroblasts (TTFs), but not in mouse embryonic ﬁbroblasts (MEFs). Mechanistically, diclo-
fenac enhanced cardiac reprogramming by inhibiting cyclooxygenase-2, prostaglandin E2/
prostaglandin E receptor 4, cyclic AMP/protein kinase A, and interleukin 1β signaling and by
silencing inﬂammatory and ﬁbroblast programs, which were activated in postnatal and adult
TTFs. Thus, anti-inﬂammation represents a new target for cardiac reprogramming associated
with aging.
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Heart disease is a leading cause of mortality in children andadults, and new therapeutic options are in high demand.Direct cardiac reprogramming converts ﬁbroblasts into
cardiomyocyte-like cells (iCMs), without passing through a stem
cell state, by the overexpression of cardiac transcription factors
including Gata4, Mef2c, and Tbx5 (GMT) or GMT plus Hand2
(GHMT)1,2. In vivo cardiac reprogramming by direct injection of
GMT or GHMT into infarct mouse hearts converted resident
cardiac ﬁbroblasts into iCMs, improved cardiac function, and
reduced ﬁbrosis after myocardial infarction (MI)2–5. Zhou et al.6
recently reported that comparative gene expression analyses
showed iCMs induced in vitro exhibited more adult
cardiomyocyte-like features, such as fatty acid oxidation and cell-
cycle exit, than exhibited by induced pluripotent stem cell (iPSC)-
derived CMs. Thus, direct cardiac reprogramming has potential
for disease modeling, drug screening, and cardiac repair, if the
iCMs can be efﬁciently generated from ﬁbroblasts7.
We and others have mainly taken a candidate approach to
identify the factors that enhance cardiac reprogramming. Recent
advances in this ﬁeld have shown that modiﬁcations of tran-
scription factors, miRNAs, epigenetic factors, deﬁned culture
conditions, and small molecules (including TGFβ Wnt inhibi-
tors), could promote cardiac reprogramming8–15. Although
silencing the ﬁbroblast (original cell type) program is a pre-
requisite for cardiac reprogramming, the molecular mechanisms
underlying this process remain poorly understood. Moreover,
improvements in reprogramming efﬁciency were shown mainly
in mouse embryonic ﬁbroblasts (MEFs), and cardiac repro-
gramming from more differentiated ﬁbroblasts, such as mouse
postnatal and adult tail-tip ﬁbroblasts (TTFs), remained inefﬁ-
cient13,16. For clinical relevance, it is desirable to generate iCMs
efﬁciently from postnatal and adult ﬁbroblasts; however, the
barriers to cardiac reprogramming associated with aging remain
undeﬁned7,17.
In this study, we developed a high-content, high-throughput
screening system, using a chemical library of 8400 compounds, to
identify small molecules that enhance cardiac reprogramming in
mouse postnatal and adult TTFs. Small molecules would be less
expensive, more easily controlled, and possibly more efﬁcient
than growth factors and cytokines, leading to efﬁcient and
reproducible cardiac reprogramming. In this study, we found
diclofenac sodium (diclofenac) greatly enhanced cardiac repro-
gramming in postnatal and adult TTFs, but not in MEFs, in
combination with GMT or GHMT. Diclofenac enhanced cardiac
reprogramming via the inhibition of cyclooxygenase-2 (COX-2)/
prostaglandin E2 (PGE2)/PGE receptor 4 (EP4)/interleukin 1β
(IL-1β)/interleukin 1 receptor type 1 (IL-1R1) signaling
and subsequent suppression of inﬂammatory and ﬁbroblast
gene programs, which were activated in postnatal and adult
ﬁbroblasts.
Results
Diclofenac promoted cardiac reprogramming in postnatal
TTFs. We previously identiﬁed cardiac reprogramming factors,
Gata4, Mef2c, and Tbx5, by analyzing cardiac reporter and pro-
tein expression in mouse ﬁbroblasts with ﬂuorescence-activated
cell sorting (FACS) analyses1. However, this method is labor-
intensive and may not be suitable to screen a large set of chemical
compounds. To screen small molecules that promote cardiac
reprogramming from chemical libraries, we developed a high-
content, high-throughput screening system, using an IN Cell
Analyzer 6000. We realized that ﬁbroblasts from alpha myosin
heavy chain (αMHC)-GFP transgenic mice exhibited auto-
ﬂuorescence in this system, hindering accurate detection of car-
diac reprogramming with GFP signals. Consequently, we
generated αMHC-Cre/R26-tdTomato mice by crossing αMHC-
Cre mice with R26R-tdTomato reporter mice, in which only
cardiomyocytes expressed tdTomato. We used αMHC-Cre/R26-
tdTomato mouse postnatal TTFs, which were not contaminated
with cardiomyocytes and did not express auto-ﬂuorescence, to
identify chemicals that promote cardiac reprogramming in dif-
ferentiated ﬁbroblasts. For chemical screening, we transduced
GMT retroviruses into αMHC-Cre/R26-tdTomato TTFs in mul-
tiple 96-well plates and added 8400 small molecules at a ﬁnal
concentration of 10 μM in each well. After 1 week, cell nuclei
were stained with Hoechst 33342, and cardiac reprogramming
efﬁciency was automatically scored by the IN Cell Analyzer 6000
as the percentage of αMHC-Cre/R26-tdTomato+ nuclei out of
the total number of nuclei (Fig. 1a). The ﬁrst screening identiﬁed
37 hit compounds that increased cardiac reprogramming efﬁ-
ciency more than the mean+ 2 SD of the control (Fig. 1b). The
second round of screening narrowed the 37 compounds down to
4, including QA-6161, STK081095, STK833231, and STK825882
(Fig. 1b, c, Supplementary Table 2). Next, to conﬁrm the effects of
these 4 compounds on cardiac reprogramming under different
conditions, we transduced GHMT into αMHC-GFP TTFs, treated
the cells with the four compounds, and after 1 week analyzed
αMHC-GFP cardiac reporter and endogenous cardiac troponin T
(cTnT) protein expression with FACS. FACS analyses showed
that all four chemicals increased the generation of αMHC-GFP+
and cTnT+ cells from postnatal TTFs (Fig. 1d, e). Intriguingly,
the most powerful compound, QA-6161, was proven to be
diclofenac (Voltaren), an FDA-approved non-steroidal anti-
inﬂammatory drug (NSAID), commonly used in humans for
the treatment of inﬂammation and rheumatic diseases (Fig. 1f),
while the functions of the other compounds remain largely
unknown. Addition of each compound individually to diclofenac
did not show additive effects on cardiac reprogramming, sug-
gesting these three compounds regulated the same signaling
pathways as diclofenac (Supplementary Fig. 1a, b). Therefore, we
focused on diclofenac in subsequent studies to determine its
effects on cardiac reprogramming
Diclofenac functioned at the early stage of reprogramming.
FACS analyses showed that 10 μM of diclofenac with GHMT
increased cardiac reprogramming efﬁciency in postnatal TTFs
about three- to fourfold, reaching a comparable level with that in
MEFs (Figs. 2a, b and 3c, d). We next analyzed the dose
dependency of diclofenac-mediated cardiac reprogramming in
αMHC-GFP postnatal TTFs with FACS. Titration of diclofenac
from 1 nM to 100 μM improved cardiac reprogramming in a
dose-dependent manner without cytotoxicity (Fig. 2a, b). Cardiac
induction was efﬁcient even at the low concentration (1 μM),
demonstrating the strong biological activity of this compound. To
determine the period during which diclofenac promoted cardiac
reprogramming, we cultured the cells with diclofenac in several
patterns and analyzed cardiac induction after 7 days with FACS.
Diclofenac treatment on days 0–4 was similarly effective as that
on days 0–7, while treatment after day 4 (days 4–7) did not
improve cardiac reprogramming. This suggests that diclofenac is
critical for iCM generation during the early stages of cardiac
reprogramming, in which the ﬁbroblast program is silenced
(Fig. 2c). Immunostaining for cardiac markers showed that
diclofenac increased the generation of αMHC-GFP+ and α-
actinin+ cells in the GHMT-transduced TTFs after 4 weeks, and
the GHMT/diclofenac-induced iCMs had well-deﬁned sarcomeric
structures (Fig. 2d, e). A quantitative reverse transcription-
polymerase chain reaction (qRT-PCR) showed that a panel of
cardiac genes related to different functions, including sarcomeric
structures (Actc1, Myh6, Tnnc1), hormones (Nppa), and ion
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08626-y
2 NATURE COMMUNICATIONS |          (2019) 10:674 | https://doi.org/10.1038/s41467-019-08626-y | www.nature.com/naturecommunications
channels (Kcnd2, Pln, Scn5a, Slc8a1), were strongly upregulated
in the reprogrammed TTFs with diclofenac (Fig. 2f).
We next analyzed the functional property characteristics of
cardiomyocytes in the GHMT/diclofenac-induced iCMs. To
detect the cells that exhibited spontaneous calcium transients,
we analyzed intracellular calcium concentrations by Rhod-3
imaging (Fig. 2g, Supplementary Movie 1). We found that the
combination of GHMT and diclofenac after 6 weeks increased the
generation of spontaneous calcium transient+ cells about two- to
threefold when compared to GHMT alone (Fig. 2h). The number
of spontaneously beating iCMs in GHMT-TTFs after 6 weeks also
increased about fourfold with the addition of diclofenac (Fig. 2i,
Supplementary Movie 2). Therefore, diclofenac promoted the
efﬁciency and quality of cardiac reprogramming in mouse
postnatal TTFs.
Diclofenac enhanced reprogramming via suppression of COX-
2. We next investigated the effect of diclofenac on cardiac
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Fig. 1 High-content screening identiﬁes small molecules for cardiac reprogramming. a, b Schematic representation of the high-content, high-throughput
screening system designed to identify small molecules for cardiac reprogramming in αMHC-Cre/R26-tdTomato TTFs in the presence of GMT. After the
second screening, FACS was performed (b). c Four compounds increased generation of αMHC-Cre/R26-tdTomato+ cells from postnatal TTFs after
1 week. See also Supplementary Table 2. d, e FACS analyses for αMHC-GFP and cTnT expression in GHMT-transduced TTFs treated with indicated
compounds for 1 week. Quantitative data are shown in e; n= 3 biologically independent experiments. See also Supplementary Figure 1. f Chemical structure
of diclofenac (QA-6161). One-way ANOVA with Dunnett’s post hoc test was performed for e; all data are presented as mean ±SEM. *P < 0.05, **P < 0.01
vs. the relevant control. Scale bars represent 100 μm
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reprogramming in adult TTFs. FACS analyses showed that car-
diac reprogramming with GHMT was less efﬁcient in adult TTFs
than in postnatal TTFs, consistent with previous reports (Figs. 2a,
b and 3a, b)13,16. However, diclofenac treatment signiﬁcantly
increased the induction of αMHC-GFP+ and cTnT+ cells (by
about threefold) to a level comparable to that in postnatal TTFs
(Figs. 2a, b and 3a, b). Moreover, addition of miR-133, a muscle
miRNA known to promote cardiac reprogramming, to GHMT/
diclofenac further enhanced cardiac induction in adult TTFs to a
similar extent as that in MEFs and diclofenac-treated postnatal
TTFs (Figs. 2a, b and 3c, d, Supplementary Fig. 2a, b). We next
analyzed the effect of diclofenac on cardiac reprogramming in
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MEFs. In contrast to the positive effects in postnatal and adult
TTFs, diclofenac did not substantially promote cardiac repro-
gramming in GHMT-transduced MEFs (Fig. 3c, d). These results
suggest that diclofenac promotes cardiac reprogramming selec-
tively in mouse postnatal and adult TTFs, but not in MEFs.
Diclofenac and other NSAIDs inhibit the activity of COX
enzymes, and thereby inhibit the biosynthesis of prostanoids18.
Two COX isoforms are known: COX-1, which is constitutively
expressed, and COX-2, which is inducible by inﬂammatory
growth factors and cytokines19. Diclofenac inhibits COX-2
activity more strongly than COX-120. Next, we analyzed each
COX gene expression in MEFs, postnatal and adult TTFs, and in
postnatal mouse hearts. QRT-PCR analyses showed that Ptgs1
(COX-1) expression was two- to threefold higher in postnatal and
adult TTFs than in MEFs and heart samples. Notably, Ptgs2
(COX-2) was strongly expressed in postnatal and adult TTFs
compared to MEFs in an age-dependent manner and was barely
detected in postnatal heart samples (Fig. 3e). Consistently, we
found that multiple inﬂammatory and ﬁbroblast-related genes,
including prostaglandin E receptor 4 (Ptger4), MCP-1 (Ccl2),
MCP-2 (Ccl8), IL-1R1 (Il1r1), Postn, and Thy1, were more
strongly expressed in postnatal and adult TTFs than in MEFs
(Fig. 3e). To investigate which COX isoform was critical for
diclofenac-mediated cardiac reprogramming, we treated the
GHMT-transduced postnatal TTFs with a COX-1 (SC-560) or
COX-2 (NS-398) speciﬁc inhibitor. FACS analyses revealed that,
like diclofenac, NS-398 (but not SC-560) greatly increased the
generation of αMHC-GFP+ and cTnT+ cells in the GHMT-
transduced TTFs (Fig. 3f, g). Of the other NSAIDs tested,
celecoxib (a COX-2 selective inhibitor) but not acetylsalicylic acid
(aspirin, a COX-1 dominant inhibitor), also improved cardiac
reprogramming (Fig. 3h–k). These results suggest that diclofenac
promotes cardiac reprogramming in TTFs mainly through the
suppression of COX-2, which was highly expressed in postnatal
and adult TTFs.
Diclofenac promoted reprogramming by suppressing PGE2/
EP4. COX enzymes synthesize prostanoids, which consist of
PGD2, PGE2, PGF2α, PGI2, and thromboxane A2 (TXA2)18. To
determine the molecular mechanism underlying diclofenac-
mediated cardiac reprogramming, each prostanoid was added to
the GHMT/diclofenac-induced TTFs. We found that the addition
of PGE2 strongly suppressed the generation of GHMT/diclofe-
nac-induced iCMs compared to other prostanoids, suggesting
suppression of PGE2 synthesis was critical for diclofenac-
mediated cardiac reprogramming (Fig. 4a, b). PGE2 binds to
four kinds of G-protein-coupled receptors, PGE receptors 1–4
(EP1-4, Ptger1-4)18,19. Although all four PGE receptors were
expressed in postnatal TTFs, Ptger4 was most abundantly
expressed in TTFs (Supplementary Fig. 3a). To determine which
PGE receptors were involved in cardiac reprogramming, we
cultured GHMT-transduced postnatal TTFs with speciﬁc
antagonists for EP1 (ONO-8713), EP2 (TG4-155), EP3 (ONO-
AE5-599), or EP4 (ONO-AE3-208). FACS analyses revealed that
the EP4 antagonist most strongly induced αMHC-GFP+ and
cTnT+ cells, while EP3 antagonist treatment showed a mild
effect. Addition of EP3 antagonist to EP4 antagonist did not
further promote cardiac reprogramming, suggesting that
EP3 shared the same downstream signaling pathways as EP4
(Figs. 4c–e and 5i, Supplementary Fig. 3b). We next suppressed
EP4 (Ptger4) expression with siRNA in GHMT-transduced TTFs
(Supplementary Fig. 3c). FACS analyses showed that knockdown
of Ptger4 also increased cardiac reprogramming from postnatal
TTFs, recapitulating the effect of diclofenac (Supplementary
Fig. 3d, e). In contrast, similar to PGE2 treatment, the addition of
the EP4 selective agonist (ONO-AE1-329) completely blocked
diclofenac-mediated cardiac reprogramming, suggesting that EP4
is a major receptor involved in diclofenac-induced cardiac
reprogramming (Supplementary Fig. 3f, g). Next, to conﬁrm the
role of EP4 in cardiac reprogramming, we used EP4-knockout
mice (Ptger4−/−). Cardiac reprogramming was greatly increased
in Ptger4−/− TTFs to a similar extent as that in EP4 antagonist/
diclofenac-treated wild-type TTFs. Addition of EP4 antagonist,
diclofenac, or PGE2 did not change cardiac induction in Ptger4−/−
TTFs, suggesting that EP4 is critical for diclofenac/PGE2-medi-
ated cardiac reprogramming (Fig. 4f, g). Consistent with the cell
type-speciﬁc effects of diclofenac on cardiac reprogramming,
Ptger4 was more highly expressed in postnatal and adult TTFs
than in MEFs (Fig. 3e). These results suggest that diclofenac
promotes cardiac reprogramming in TTFs mainly through the
inhibition of PGE2/EP4 signaling.
cAMP/PKA activation pathway blocked cardiac reprogram-
ming. After 4 weeks of treatment, we analyzed the effects of the
PGE2/EP4 pathway on diclofenac-induced cardiac reprogram-
ming using immunohistochemistry in postnatal and adult TTFs.
Immunostaining for the cardiac markers αMHC-GFP, cTnT, and
α-actinin showed that PGE2 addition strongly suppressed
GHMT/diclofenac-induced cardiac reprogramming in postnatal
and adult TTFs (Fig. 5a, b, Supplementary Fig. 4a, b). After
4 weeks of treatment, the EP4 antagonist (ONO-AE3-208)
strongly enhanced iCM generation, whereas the EP4 speciﬁc
agonist (ONO-AE1-329) or PGE2 suppressed diclofenac-
mediated cardiac reprogramming, consistent with the FACS
data (Fig. 5c, d, Supplementary Fig. 4a, b). The qRT-PCR analyses
also revealed that a panel of cardiac genes, including Tnnc1,
Nppa, Gja1, Kcnd2, Pln, and Scn5a, were upregulated with the
addition of the EP4 antagonist and downregulated with the
Fig. 2 Diclofenac promotes the efﬁciency and quality of cardiac reprogramming in TTFs. a, b Dose dependency of Diclofenac-mediated cardiac
reprogramming in postnatal αMHC-GFP TTFs in combination with GHMT. Quantitative data are shown in b; n= 4 biologically independent experiments.
c GHMT-transduced TTFs were cultured with (red bars, left) or without (black bars) diclofenac as indicated for 1 week. FACS analyses for αMHC-GFP and
cTnT expression in three independent triplicate experiments are shown (right). D indicates days. d, e Immunocytochemistry for αMHC-GFP, α-actinin, and
DAPI. GHMT/diclofenac induced more αMHC-GFP and α-actinin expression than GHMT alone in TTFs after 4 weeks. High-magniﬁcation views in insets
show the sarcomeric organization. Quantitative data are shown in e; n= 5 biologically independent experiments. f QRT-PCR for cardiac gene expression in
the control-, GHMT-, and GHMT/diclofenac-treated TTFs after 1 week; n= 3 biologically independent experiments. g Spontaneous Ca2+ oscillations in the
GHMT/diclofenac-induced iCMs at 6 weeks after transduction. Maximum and minimum concentrations of Ca2+ signals are shown in the upper panels,
and the Rhod-3 intensity trace is shown in the lower panel. See also Supplementary Movie 1. h Quantitative data of the number of Ca2+ oscillation+ cells
after 6 weeks are shown; n= 5 biologically independent experiments. i Quantitative data of the number of spontaneously beating cells in control-, GHMT-,
and GHMT/diclofenac-treated TTFs after 6 weeks are shown; n= 3 biologically independent experiments. See also Supplementary Movie 2. Student’s t-
test was performed for e, f, g, i, one-way ANOVA with Dunnett’s post hoc test was performed for b, c; all data are presented as mean ±SEM. *P < 0.05, **P
< 0.01 vs. the relevant control. ND, not detected. Diclo, diclofenac. Scale bars represent 100 μm (d) and 1 s (g)
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addition of the EP4 agonist or PGE2 in both TTFs (Fig. 5e,
Supplementary Fig. 4c), suggesting that diclofenac promotes
cardiac reprogramming in postnatal and adult TTFs through the
inhibition of PGE2/EP4 signaling.
PGE2/EP4 signaling activates the cAMP/PKA pathway through
Gs, however, the role of the cAMP/PKA pathway in cardiac
reprogramming remains undetermined18. Forskolin activates
adenylyl cyclase and increases the intracellular level of cAMP,
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Fig. 3 Diclofenac promotes cardiac reprogramming in adult TTFs but not in MEFs. a, b FACS analyses for αMHC-GFP and cTnT expression in adult TTFs
transduced with GHMT and cultured with or without diclofenac for 1 week. Quantitative data are shown in b; n= 3 biologically independent experiments.
See also Supplementary Figure 2. c, d FACS analyses for αMHC-GFP and cTnT expression in MEFs transduced with GHMT and cultured with or without
diclofenac for 1 week. Quantitative data are shown in d; n= 3 biologically independent experiments. e Relative mRNA expression levels were determined in
MEFs, postnatal and adult TTFs, and postnatal heats by qRT-PCR; n= 3 biologically independent experiments. f, g FACS analyses for αMHC-GFP and cTnT
expression in postnatal TTFs transduced with GHMT and treated with indicated reagents for 1 week; inh indicates inhibitor. Quantitative data are shown in
g; n= 3 biologically independent experiments. h–k FACS analyses for αMHC-GFP and cTnT expression in postnatal TTFs transduced with GHMT and
treated with celecoxib (h) or acetylsalicylic acid (ASA, j) for 1 week. Quantitative data are shown in i and k, respectively; n= 3 biologically independent
experiments. Student’s t-test was performed for b, d, i, k, one-way ANOVA with Dunnett’s post hoc test was performed for e, g; all data are presented as
mean ± SEM. *P < 0.05, **P < 0.01 vs. the relevant control. NS, not signiﬁcant. Diclo, diclofenac
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Fig. 4 Diclofenac promotes cardiac reprogramming via inhibition of the PGE2/EP4 pathway. a, b FACS analyses for αMHC-GFP and cTnT expression.
Postnatal αMHC-GFP TTFs were transduced with GHMT and cultured with the indicated prostanoids for 1 week. Quantitative data are shown in b; n= 3
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NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08626-y ARTICLE
NATURE COMMUNICATIONS |          (2019) 10:674 | https://doi.org/10.1038/s41467-019-08626-y |www.nature.com/naturecommunications 7
while dibutyryl-cAMP (db-cAMP) is an analog of cyclic AMP
that stimulates PKA signaling. We found that these two activators
of the cAMP/PKA pathway both counteracted diclofenac-
mediated cardiac reprogramming in postnatal and adult TTFs,
as shown by FACS and qRT-PCR (Fig. 5f–h, Supplementary
Fig. 4d-f). These results suggest that diclofenac promotes cardiac
reprogramming, at least in part, via the inhibition of the cAMP/
PKA pathway. Consistent with this, the intracellular cAMP level
was strongly downregulated by EP4 antagonist (Fig. 5i). EP3
couples with both Gs and Gi to activate and inhibit adenylyl
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cyclase/cAMP signaling, respectively21,22. We found that EP3
antagonist mildly repressed cAMP expression, and addition of
EP3 antagonist to EP4 antagonist did not further downregulate
the cAMP level, consistent with the cardiac reprogramming
efﬁciency induced by EP3 and EP4 antagonists (Fig. 4c–e,
Supplementary Fig. 3b). Thus, EP3 and EP4 antagonists may
inhibit the same cAMP pathway to promote cardiac
reprogramming.
Diclofenac suppressed inﬂammation and ﬁbroblast signatures.
To investigate the mechanisms responsible for diclofenac-
mediated cardiac reprogramming, we used microarray analyses
to determine the global gene expression proﬁles of GHMT-
transduced TTFs with and without diclofenac, after 1 week. We
also analyzed the gene expression in GHMT-TTFs treated with an
EP4 antagonist (ONO-AE3-208), as the addition of the EP4
antagonist showed similar effects on cardiac reprogramming as
diclofenac did. Differential gene expression analyses revealed that,
compared to GHMT alone, 290 genes were upregulated after
either diclofenac or EP4 antagonist treatment, while 241 genes
were downregulated at least twofold, with signiﬁcant overlaps
between the two groups (Fig. 6a, b, d). Gene ontology (GO)
analyses showed that the upregulated genes in both diclofenac
and EP4 antagonist treatment were signiﬁcantly enriched for GO
terms associated with cardiac function and development, while
the downregulated genes were signiﬁcantly enriched for GO
terms associated with ﬁbroblast signatures (extracellular matrix
and collagen ﬁbril organization) and inﬂammatory responses
(positive regulation of response to stimulus and cytokine pro-
duction) (Fig. 6c, e). Microarray data revealed that a panel of
cardiac genes were upregulated, while ﬁbroblast and inﬂamma-
tory genes, such as Tgfbi, Col1a2, Fbln1, Mcpt8, Il1r1, and Tnfsf4,
were downregulated with diclofenac (Fig. 6f). We next investi-
gated whether PGE2 supplementation could globally counteract
diclofenac-mediated gene regulation. We found that, of the 218
genes upregulated by diclofenac, 209 were suppressed by
PGE2 supplementation. In contrast, 139 of the 161 genes
downregulated by diclofenac, were upregulated by PGE2, sug-
gesting that most parts of the transcriptional changes affected by
diclofenac were mediated via the suppression of PGE2 synthesis
(Fig. 6g).
Previous studies showed that TGFβ and Wnt inhibitors
promoted cardiac reprogramming11,12,23. We asked whether
diclofenac promoted cardiac reprogramming through TGFβ or
Wnt pathway inhibition. FACS analyses showed that the
induction of αMHC-GFP+/cTnT+ iCMs was signiﬁcantly
stronger upon diclofenac treatment than upon TGFβ (A83-01)
or Wnt inhibitor (IWR-1) treatment (Fig. 6h, i). Addition of
diclofenac to TGFβ or Wnt inhibitor further increased cardiac
reprogramming efﬁciency (Fig. 6h, i), suggesting that diclofenac
promotes cardiac reprogramming via mechanisms other than
inhibition of the TGFβ or Wnt signaling pathways. We next
analyzed the time course of cardiac reprogramming required for
each molecule to promote the generation of iCMs. Sequential
FACS analyses revealed that diclofenac started to increase iCM
generation after just 2 days, whereas TGFβ and Wnt inhibitors
enhanced iCM generation after 7–10 days, suggesting that
diclofenac promoted cardiac reprogramming more rapidly and
efﬁciently than the other molecules (Fig. 6j). We next analyzed
the global gene expression proﬁles after treatment with EP4
antagonist, TGFβ inhibitor, and Wnt inhibitor by microarray. GO
term analyses revealed that all three reagents upregulated 51
genes related to cardiac function and muscle structures, whereas
EP4 antagonist speciﬁcally suppressed 203 genes associated with
inﬂammatory and ﬁbroblast signatures (Supplementary Fig. 5a-
d). These results suggest that EP4 antagonist enhances cardiac
reprogramming via suppression of inﬂammation and the
ﬁbroblast program in postnatal TTFs.
Suppression of IL-1β/IL-1R1 improved cardiac reprogram-
ming. COX-2/PGE2/EP4 activates inﬂammatory responses,
including the IL-1β (Il1b), MCP-1 (Ccl2), and IL-6 (Il6) pathways.
We found that Il1b, its receptor IL-1R1 (Il1r1), and Ccl2, but not
Il6, were strongly suppressed by EP4 antagonist (Fig. 7a). To
determine the molecular mechanism underlying PGE2/EP4-
mediated cardiac reprogramming, each cytokine (IL-1β, MCP-1,
or IL-6) was added to GHMT/EP4 antagonist-treated TTFs.
Addition of IL-1β, but not MCP-1 nor IL-6, suppressed cardiac
reprogramming, suggesting EP4 antagonist promoted cardiac
reprogramming via suppression of IL-1β/IL-1R1 signaling
(Fig. 7b, c). Addition of IL-1β upregulated multiple inﬂammatory
and ﬁbroblast genes, such as Ccr1, Cxcl3, Il33, Col12a1, Snai1, and
Timp1, and downregulated cardiac gene expression as shown by
qRT-PCR (Fig. 7d). Intriguingly, COX-2 selective inhibitor (NS-
398) strongly suppressed Il1b, while COX-1 selective inhibitor
(SC-560) did not, consistent with the speciﬁc effect of COX-2
inhibitors on cardiac reprogramming (Figs. 3f–k and 7e).
Next, to determine whether suppression of IL-1β/IL-
1R1 signaling could improve cardiac reprogramming, we knocked
down IL-1R1 expression with siRNA (si-Ilr1) in GHMT-
transduced TTFs (Fig. 7f). FACS analyses revealed that knock-
down of Il1r1 greatly increased cardiac reprogramming in
postnatal TTFs, recapitulating the effects of EP4 antagonist
(Fig. 7g, h). Moreover, addition of si-Il1r1 to EP4 antagonist did
not further increase cardiac reprogramming, suggesting EP4 and
IL-1R1 signaling acted via the same pathways (Fig. 7i, j). QRT-
PCR revealed that a panel of inﬂammation- and ﬁbroblast-related
genes, including Cxcl11, Cxcl14, Il33, Col1a1, Fn1, and Postn,
were signiﬁcantly downregulated, while cardiac genes, such as
Actc1, Nppa, and Pln, were upregulated by si-Il1r1 treatment
Fig. 5 Activation of cyclic AMP/protein kinase A pathway inhibits diclofenac-induced cardiac reprogramming. a, b Immunocytochemistry for αMHC-GFP,
cTnT, and DAPI. PGE2 treatment inhibited GHMT/diclofenac-induced cardiac protein expression in postnatal TTFs after 4 weeks. High-magniﬁcation
views, insets, show the sarcomeric organization. Quantitative data are shown in b; n= 5 biologically independent experiments. See also Supplementary
Figure 4. c, d Immunocytochemistry for αMHC-GFP, α-actinin, and DAPI. EP4 antagonist (ant) and diclofenac treatment increased generation of iCMs,
while EP4 agonist (ago) inhibited GHMT/diclofenac-induced cardiac reprogramming in TTFs after 4 weeks. High-magniﬁcation views, insets, show the
sarcomeric organization. Quantitative data are shown in d; n= 5 biologically independent experiments. e qRT-PCR analyses for cardiac gene expression in
postnatal TTFs transduced with GHMT and treated with or without indicated reagents for 1 week; n= 3 biologically independent experiments. f, g FACS
analyses for αMHC-GFP+ and cTnT+ cells. GHMT-transduced TTFs were cultured with diclofenac with or without forskolin or dibutyryl-cAMP (Db-cAMP)
for 1 week. Quantitative data are shown in g; n= 3 biologically independent experiments. h qRT-PCR analyses for cardiac gene expression in postnatal TTFs
treated as indicated for 1 week; n= 3 biologically independent experiments. i Concentration of intracellular cAMP in GHMT-transduced TTFs treated with
the indicated EP antagonists (ant); n= 4 biologically independent experiments. One-way ANOVA with Tukey’s post hoc test was performed for b, d, e, g–i.
All data are presented as mean ±SEM. *P < 0.05, **P < 0.01 vs. the relevant control. NS, not signiﬁcant. Diclo, diclofenac. Scale bars represent 100 μm
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(Fig. 7k). These results suggest that inhibition of the COX-2/
PGE2/EP4 pathway promotes cardiac reprogramming via sup-
pression of IL-1β/IL-1R1 signaling and silencing of inﬂammatory
and ﬁbroblast signatures in TTFs.
Discussion
We have developed a high-throughput, high-content screening
system to identify small molecules that promote cardiac
reprogramming. We found that a traditional NSAID, diclofenac,
greatly promoted cardiac reprogramming in mouse postnatal and
adult TTFs, but not in MEFs, by suppressing COX-2/PGE2/EP4
pathways and silencing inﬂammatory and ﬁbroblast gene
expression. To our knowledge, this is the ﬁrst report identifying
the cardiac reprogramming barriers associated with aging.
Previous studies mainly used a candidate approach to identify
cardiac reprogramming factors such as transcription factors,
miRNAs, growth factors, and small molecules1,10–13. Factors were
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selected based on information related to cardiogenesis and car-
diac differentiation from PSCs. Although this approach advanced
cardiac reprogramming research, improvements in reprogram-
ming were mainly found in MEFs, with limited success in post-
natal and adult TTFs13,16. In this study, we took an unbiased
approach to identify small molecules that promote cardiac
reprogramming in postnatal and adult TTFs. We found that
diclofenac greatly promoted cardiac reprogramming in mouse
postnatal and adult TTFs but not in MEFs. Given that diclofenac
and other NSAIDs were not indicated in cardiac differentiation in
embryos or from PSCs, our unbiased screening was necessary to
identify diclofenac as a cardiac reprogramming-inducing reagent.
We anticipate that our screening system will be equally useful in
identifying new reagents for cardiac reprogramming in other cell
types, such as human aged ﬁbroblasts.
Diclofenac promoted cardiac reprogramming in TTFs via the
suppression of COX-2/PGE2/EP4/cAMP/PKA/IL-1β/IL-
1R1 signaling, with the inhibition of inﬂammatory and ﬁbroblast
gene expression. COX-2 is a rate-limiting and inducible enzyme of
the prostanoid biosynthetic pathway, eliciting inﬂammation,
immune response, and pyrexia18,19. We found that not only
diclofenac but also other COX-2 speciﬁc inhibitors (NS-398 and
celecoxib) promoted cardiac reprogramming. In contrast, neither a
COX-1 inhibitor (SC-560) nor acetylsalicylic acid substantially
improved cardiac reprogramming, suggesting that COX-2 is a main
target for diclofenac-induced cardiac reprogramming. Consistently,
IL-1β, a barrier for cardiac reprogramming, was suppressed by the
COX-2 inhibitor but not by the COX-1 inhibitor. We also found
that PGE2 and an EP4 selective agonist both suppressed diclofenac-
mediated cardiac reprogramming, whereas the inhibition of EP4
(with a speciﬁc antagonist, using siRNA, or in knockout mice)
greatly increased cardiac reprogramming efﬁciency to a similar
extent as diclofenac treatment. This suggests that PGE2/EP4
receptor is a major pathway for diclofenac-induced cardiac repro-
gramming. Consistent with this, microarray analyses revealed that
the global transcriptional changes induced by diclofenac sig-
niﬁcantly overlapped with those induced by EP4 antagonist, which
were largely reversed by PGE2 supplementation. A G-protein-
coupled receptor, EP4 stimulates adenylyl cyclase via Gs, leading to
activation of the cAMP/PKA pathway18. The cAMP level was
strongly downregulated by EP4 antagonist, and forskolin and db-
cAMP, activators of this pathway, suppressed diclofenac-mediated
cardiac reprogramming, suggesting that inhibition of the cAMP/
PKA pathway is critical for diclofenac/EP4 antagonist-mediated
cardiac reprogramming.
We also found that diclofenac induced more efﬁcient and rapid
cardiac reprogramming than TGFβ inhibitor or Wnt inhibitor
and that addition of diclofenac to TGFβ or Wnt inhibitor-
enhanced cardiac reprogramming, suggesting that diclofenac
induced cardiac reprogramming through mechanisms other than
the inhibition of TGFβ or Wnt signaling. GO term analyses
demonstrated that EP4 antagonist, TGFβ inhibitor, and Wnt
inhibitor all upregulated cardiac-related genes, whereas EP4
antagonist speciﬁcally suppressed inﬂammation- and ﬁbroblast-
related genes in TTFs. Intriguingly, EP4 antagonist suppressed IL-
1β and IL-1R1 expression in ﬁbroblasts, and supplementation of
IL-1β increased inﬂammatory and ﬁbroblast genes and inhibited
cardiac reprogramming. In contrast, inhibition of IL-1β/IL-
1R1 signaling promoted cardiac reprogramming via suppression
of inﬂammatory and ﬁbroblast signatures. These results demon-
strated that diclofenac/EP4 antagonist promoted cardiac repro-
gramming through inhibition of IL-1β/IL-1R1 signaling and
suppression of inﬂammatory and ﬁbroblast programs. Notably,
we found that COX-2, EP4, and multiple inﬂammation- and
ﬁbroblast-related genes were more strongly expressed in postnatal
and adult TTFs than in MEFs, consistent with the cell type-
speciﬁc effects of diclofenac on cardiac reprogramming. Thus,
active inﬂammation and subsequent ﬁbrogenesis could be an age-
related barrier to cardiac reprogramming. Consistent with this,
Zhou et al.24 recently reported that zinc ﬁnger transcription factor
281 (ZNF281) enhanced cardiac reprogramming by modulating
cardiac and inﬂammatory gene expression in adult ﬁbroblasts.
Given that the silencing of ﬁbroblast signatures is a prerequisite
for reprogramming, anti-inﬂammation may represent a potential
target for other lineage conversions associated with aging25.
The PGE2/EP4 pathway regulates not only inﬂammation but also
non-inﬂammatory pathways, such as vascular development and
endothelial cell function26. Future studies are needed to determine
the non-inﬂammatory mechanisms involved in PGE2/EP4-medi-
ated cardiac reprogramming. We also found that the cardiac
reprogramming efﬁciency in diclofenac-treated adult TTFs was still
lower than that in diclofenac-treated postnatal TTFs and that
addition of miR-133 promoted cardiac reprogramming in
diclofenac-treated adult TTFs to a degree comparable to that in
diclofenac-treated postnatal TTFs. Thus, postnatal and adult TTFs
are different, and inhibition of inﬂammatory responses alone may
not be sufﬁcient for reprogramming, at least in the context of adult
ﬁbroblasts. Identiﬁcation of epigenetic barriers and other key
molecules will provide new insights into the mechanism of cardiac
reprogramming and improve reprogramming efﬁciency in aged
Fig. 6 Diclofenac activates cardiac program and suppresses ﬁbroblast and inﬂammatory gene expression during cardiac reprogramming. a Heatmap images
of microarray data illustrating differentially expressed genes between either GHMT and GHMT/diclofenac (Diclo) or GHMT and GHMT/EP4 antagonist
(ant)-induced TTFs, after 1 week. b, c Venn diagram showing the genes that are upregulated in postnatal TTFs with GHMT/diclofenac (Diclo, red) or
GHMT/EP4 antagonist (ant, blue) by more than twofold compared to GHMT alone. GO analyses of the 97 upregulated genes in both GHMT/diclofenac
and GHMT/EP4 antagonist (ant) treatment are shown in c. Cardiac-related GO terms are shown. d, e Venn diagram showing the genes that are
downregulated in postnatal TTFs with GHMT/diclofenac (Diclo, red) or GHMT/EP4 antagonist (ant, blue) treatment by more than twofold compared to
GHMT alone. GO analyses of the 71 downregulated genes in both GHMT/diclofenac and GHMT/EP4 antagonist (ant) treatment are shown in e. Fibroblast
and inﬂammatory-related GO terms are shown. f The relative mRNA expression after 1 week of cardiomyocyte, ﬁbroblast, and inﬂammation genes in
GHMT/diclofenac-TTFs compared to GHMT-TTFs by microarray. g Heatmap image of microarray data for GHMT-, GHMT/diclofenac-, and GHMT/
diclofenac/PGE2-treated TTFs after 1 week of transduction (left panel). Differentially expressed genes between GHMT-TTFs and GHMT/diclofenac-TTFs
are shown; 209 out of 218 upregulated genes were suppressed by PGE2 addition (right upper panel), while 139 out of 161 downregulated genes were
increased with PGE2 (right lower panel). h, i FACS analyses for αMHC-GFP+ and cTnT+ cells. GHMT-transduced TTFs were treated as indicated for
1 week. Quantitative data are shown in i; n= 3 biologically independent experiments. See also Supplementary Figure 5. j Time course of FACS analyses for
αMHC-GFP+ and cTnT+ cells. Diclofenac induced cardiac reprograming more rapidly than other inhibitors. n= 4 biologically independent experiments.
One-way ANOVA with Tukey’s post hoc test was performed for i, two-way ANOVA with Tukey’s post hoc test was performed for j. All data are presented
as mean ±SEM. *P < 0.05, **P < 0.01 vs. the relevant control. NS, not signiﬁcant; The scales are –1 to+1 in log10 (a) and −2 to+2 in log10 (g). Diclo,
diclofenac
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ﬁbroblasts. A recent paper showed that, compared with GMT alone,
the delivery of TGFβ and Wnt inhibitors in the presence of GMT
improved in vivo cardiac reprogramming and enhanced cardiac
repair after MI in mice23. It would be interesting to determine
whether diclofenac promotes in vivo cardiac reprogramming and
improves cardiac function after MI, with TGFβ and Wnt inhibitors
for regenerative purposes.
In summary, we developed a high-content screening system to
identify small molecules for cardiac reprogramming. We found
that diclofenac promoted cardiac reprogramming in postnatal and
adult ﬁbroblasts. Given that cardiac diseases affect child and adult
patients, our results are of relevance for future applications in
disease modeling, drug discovery, and regenerative medicine. Use
of the high-content screen will allow for identiﬁcation of new
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reagents and advance cardiac reprogramming technology toward
clinical applications.
Methods
Mouse strains. The Keio University Ethics Committee for Animal Experiments
approved all experiments in this study. Transgenic mice overexpressing GFP under
the αMHC promoter were generated as described previously1. αMHC-Cre/R26-
tdTomato mice were generated by crossing αMHC-Cre mice and R26R-tdTomato
reporter mice (The Jackson Laboratory)27. Generation of EP4-knockout mice
(Ptger4−/−) has been reported previously28.
Quantitative and semiquantitative RT-PCR. Total RNA was isolated from the
cells, and a qRT-PCR was performed using SYBR green technology (TOYOBO Life
Science) or the Viia7 Real-Time PCR system (Roche or Applied Biosystems) fol-
lowing standard protocols. Details of primers and probes are provided in Sup-
plementary Table 1. Semiquantitative RT-PCR for PGE receptors was performed
with following primers: Ptger1 (Applied Biosystems, Mm00443098_g1), Ptger2
(Applied Biosystems, Mm00436051_m1), Ptger3 (Applied Biosystems,
Mm01316856_m1), Ptger4 (Applied Biosystems, Mm00436053_m1). Reactions
were conducted in a Veriti 96-well Thermal Cycler (Applied Biosystems). An initial
incubation of 10 min at 95 °C was followed by 36 cycles of 1 s at 95 °C and 20 s at
60 °C. PCR products were identiﬁed by electrophoresis on a 2% agarose gel and
visualized by ethidium bromide staining. The mRNA levels were normalized to
those of Gapdh.
Fibroblast isolation. Fibroblast isolation (of MEFs and postnatal and adult TTFs)
was performed as described previously8. For MEF isolation, embryos isolated from
12.5-day pregnant mice were washed with phosphate-buffered saline (PBS), fol-
lowed by careful removal of the head and visceral tissues. The remaining parts of
the embryos were washed in fresh PBS, minced using a pair of scissors, transferred
to a 0.125% trypsin/ethylenediaminetetraacetic acid (EDTA) solution (Gibco,
25200-072; 3 mL per embryo), and incubated at 37 °C for 20 min. An additional 3
mL of trypsin/EDTA solution was then added, and the mixture was further
incubated at 37 °C for 20 min. After trypsinization, an equal amount of medium (6
mL of Dulbecco’s modiﬁed Eagle medium, DMEM, containing 10% fetal bovine
serum, FBS, per embryo) was added and pipetted several times to allow for tissue
dissociation. After incubation of the tissue/medium mixture for 5 min 25 °C, the
supernatant was transferred to a fresh tube. Cells were collected by centrifugation
and resuspended for culturing in DMEM/10% FBS (Thermo Scientiﬁc,
SV30014.03) at 37 °C in 5% CO2. For TTF isolation, postnatal day 1–3 or 8–week-
old adult mouse tails were minced into pieces smaller than 1 mm3 (ref.12). The
explants were plated on gelatin-coated dishes and cultured for 10–14 days in
explant medium (IMDM with L-glutamate and 25 mM HEPES, Gibco, 12440-053,
20% FBS). Fibroblasts that migrated were harvested and ﬁltered with 40 μm cell
strainers (BD Biosciences) to avoid contamination with tissue fragments. The
MEFs and TTFs were plated at a density of 1 × 104 cells/cm2 for virus transduction.
Retroviral infection and cell culture. To construct pMXs retroviral vectors, we
ampliﬁed the coding regions of GFP, Gata4, Mef2c, Tbx5, and Hand2 by PCR and
subcloned them into respective pMXs vectors for transfection into Plat-E cells
using Fugene 6 (Promega, E2691) to generate retroviruses1. Fibroblasts were
transduced with the retrovirus mixtures as indicated. An siRNA Negative Control
(20 μM, Thermo Scientiﬁc, 12935-100), siGENOME Mouse Ptger4 siRNA-
SMARTpool (20 μM, Dharmacon, M-048700-01-0005), siGENOME Mouse Il1r1
siRNA-SMARTpool (20 μM, Dharmacon, M-046644-01-0005), miRIDIAN
microRNA Mimic Negative Control #2 (20 μM, Thermo Scientiﬁc, CN-002000-01-
05), or miRIDIAN microRNA Mouse mmu-miR-133a-Mimic (20 μM, Thermo
Scientiﬁc, C-310407-07-0005) was transfected simultaneously with retroviruses
into cells with Lipofectamine 2000 (Invitrogen, 11668019). The medium was
replaced with FBS medium after 24 h of infection and changed to FFV medium
after 2 weeks, as shown previously12. FBS medium contained DMEM (high glu-
cose) with L-glutamate and phenol red (Wako, Tokyo, Japan, 044-29765); Med-
ium199 with Earle’s Salts, L-glutamate and 22 g/L sodium bicarbonate (Gibco,
11150-059); and 10% Hyclone Characterized FBS (Thermo Scientiﬁc, SV30014.03).
FFV medium contained StemPro-34 SF medium (Gibco, 10639-011), GlutaMAX
(10 μL/mL, Gibco, 35050-061), ascorbic acid (50 μg/mL, Sigma Aldrich, A-4544),
recombinant human VEGF165 (5 ng/mL, R&D Systems, 293-VE-050), recombi-
nant human FGF basic 146 aa (10 ng/mL, R&D Systems, 233-FB-025), and
recombinant human FGF10 (50 ng/mL, R&D Systems, 345-FG-025). Diclofenac
(10 μM, Calbiochem, 287840), SC-560 (10 μM, Cayman, 70340), NS-398 (10 μM,
Cayman, 70590), celecoxib (10 μM, Cayman, 10008672), acetylsalicylic acid (10
μM, Sigma Aldrich, A5376), PGD2 (1 μM, Cayman, 12010), PGE2 (1 μM, Cayman,
14010), PGF2α (100 nM, Cayman, 16010), PGI2 (1 μM, Cayman, 18220), TXA2 (1
μM, Cayman, 19600), ONO-8713 (1 μM), TG4-155 (1 μM, Focus Biomolecules, 10-
1574), ONO-AE5-599 (1 μM), ONO-AE3-208 (1 μM), ONO-AE1-329 (1 μM),
forskolin (10 μM, Enzo Life Science, BML-CN100-0010), Db-cAMP (250 μM,
Wako, 023-16381), A83-01 (0.5 μM, Tocris, 2939), IWR-1 (1 μM, Sigma Aldrich,
I0161), IL-1β (10 ng/mL, Wako, 094-04681), IL-6 (100 ng/mL, Wako, 093-04433),
or MCP-1 (100 ng/mL, Wako, 131-16691) were added simultaneously with ret-
rovirus infection in the indicated experiments. The medium was changed every
3 days.
High-content screening. αMHC-Cre/R26-tdTomato TTFs were plated in 96-well
plates at a density of 3000 cells per well. Cells were reprogrammed with the GMT
retrovirus as described above. The compounds were added simultaneously to the
wells to reach to 10 μM of ﬁnal concentration with a 1:100 dilution of the drug-
library. We screened libraries of 8400 toxicologically tested compounds (TMDU
chemical library). Among the 96 wells tested, 16 and 80 wells were used for
controls (1% DMSO) and chemical compound treatment, respectively. At day 1 of
reprogramming, the medium was replaced with FBS medium. After 1 week of
reprogramming, cell nuclei were stained with Hoechst 33342, and cardiac repro-
gramming efﬁciency was automatically scored as the percentage of αMHC-Cre/
R26-tdTomato+ nuclei out of the total nuclei, using an IN Cell Analyzer 6000 (GE
Healthcare Life Sciences). Data were analyzed using the IN Cell Analyzer 6000
image-analysis package and normalized as fold change compared to the DMSO
control. Hit compounds were deﬁned as those higher than the DMSO control
mean+ 2 SD.
FACS analyses. For αMHC-GFP/cTnT expression, cells were ﬁxed with 4% par-
aformaldehyde (PFA; MUTO PURE CHEMICALS, Tokyo, Japan, 3311-1) for 15
min and permeabilized with saponin (Sigma Aldrich, 47036-250G-F). They were
stained with anti-cTnT (Thermo Scientiﬁc, MS-295-P1, 1:100) and anti-GFP
(MBL, 598, 1:500) antibodies, followed by secondary antibodies conjugated with
Alexa Fluor 488 (Invitrogen, A11008, 1:200) or 647 (Invitrogen, A21240, 1:200)1.
Cells were then analyzed using a ﬂow cytometer (Beckman Coulter, CytoFLEX S)
with CytExpert (Beckman Coulter). As negative controls for FACS gating, cells
were stained with isotype control antibodies.
Immunocytochemistry. Cells were ﬁxed in 4% PFA for 15 min at room tem-
perature, blocked with 5% normal goat serum blocking solution (Vector Labora-
tories, S-1000), and incubated with primary antibodies against cTnT (Thermo
Scientiﬁc, MS-295-P1, 1:100), GFP (MBL, 598, 1:500), or sarcomeric α-actinin
(Sigma Aldrich, 111M4845, 1:800). Cells were then incubated with secondary
antibodies conjugated with Alexa Fluor 488 (Invitrogen, A11008, 1:200) or 546
(Invitrogen, A11003, 1:200), followed by DAPI (Invitrogen, D1306) counter-
staining. The percentage of cells immunopositive for GFP, α-actinin, and cTnT
were counted in 10–15 randomly selected ﬁelds per well in ﬁve independent
experiments. A total of 2000–4000 cells were counted. The measurements and
calculations were conducted in a blinded manner.
Fig. 7 EP4 antagonist induces cardiac reprogramming via inhibition of IL-1β/IL-1R1 signaling. a The relative mRNA expression in GHMT/EP4 antagonist-
TTFs compared to GHMT-TTFs by microarray. See also Fig. 6. b, c FACS analyses for αMHC-GFP+ and cTnT+ cells. GHMT-transduced TTFs were cultured
with EP4 antagonist with or without IL-1β, IL-6, or MCP-1 for 1 week. Quantitative data are shown in c; n= 4 biologically independent experiments.
d Relative mRNA expression in GHMT/EP4 antagonist-TTFs with or without IL-1β; n= 4 biologically independent experiments. e qRT-PCR analyses of
inﬂammatory gene expression in postnatal TTFs treated with COX inhibitors for 1 week; n= 4 biologically independent experiments. f Relative mRNA
expression of Il1r1 in GHMT-TTFs transfected with scrambled siRNA or si-Il1r1; n= 5 biologically independent experiments. g, h FACS analyses for αMHC-
GFP+ and cTnT+ cells. GHMT-transduced TTFs were cultured with or without si-Il1r1 or EP4 antagonist (ant) for 1 week. Quantitative data are shown in
h; n= 4 biologically independent experiments. i, j FACS analyses for αMHC-GFP+ and cTnT+ cells. GHMT-transduced TTFs were cultured with EP4
antagonist (ant) with or without si-Il1r1 for 1 week. Quantitative data are shown in j; n= 4 biologically independent experiments. k Relative mRNA
expression of inﬂammatory genes, ﬁbroblast genes, and cardiac genes in GHMT-TTFs transfected with scrambled siRNA or si-Il1r1; n= 4 biologically
independent experiments. Student’s t-test was performed for d, f, k, one-way ANOVA with Dunnett’s post hoc test was performed for h, one-way ANOVA
with Tukey’s post hoc test was performed for c, e, j; all data are presented as mean ±SEM. *P < 0.05, **P < 0.01 vs. the relevant control. NS, not signiﬁcant
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Ca2+ imaging and counting beating cells. Ca2+ imaging was performed fol-
lowing standard protocols. Brieﬂy, cells were labeled with Rhod-3 from a Calcium
Imaging Kit (Invitrogen, R10145) for 1 h at room temperature, washed, and
incubated for an additional hour, to allow de-esteriﬁcation of the dye. Rhod-3-
labeled cells were analyzed at 37 °C using an All-in-One ﬂuorescence microscope
(BZ-9000; Keyence, Tokyo, Japan)12. Ca2+ oscillations could only be imaged for a
short period, owing to the increasing background ﬂuorescence from the medium;
thus, the measurements were taken within 30 min after changing to Tyrode’s
buffer. Ca2+ oscillation+ cells were counted in 15 randomly selected ﬁelds per well
in at ﬁve independent experiments.
To count the number of beating cells, we seeded 25,000 ﬁbroblasts per well on
24-well plates, performed cell transductions, cultured the cells, and then monitored
cell contractions. For accurate analyses of the cell count, we used the All-in-One
ﬂuorescence microscope as described previously12. The cells were maintained at 37
°C and 5% CO2, using the controlled chamber within the microscope. We ﬁrst
acquired images of the cells in all the areas in a well with a ×20 phase-contrast lens
by moving the motorized stage sequentially. We next moved the ﬁeld to cover all
the areas in a well, and counted the number of spontaneously contracting cells in
each ﬁeld with the ×20 phase-contrast lens in three independent experiments. We
identiﬁed the individual beating iCMs based on differences in beating frequency,
cell membrane boundary, and nuclei identiﬁed by the phase-contrast and GFP
ﬂuorescence ﬁlter. The number of Ca2+ transient+ or beating cells were divided
based on region of interest areas and shown as the number per cm2. The
measurements and calculations were conducted in a blinded manner.
Microarray analyses. After 1 week of reprogramming, RNA was extracted from
GHMT-, GHMT/diclofenac-, GHMT/EP4 antagonist-, GHMT/diclofenac/PGE2-,
GHMT/TGFβ inhibitor-, or GHMT/Wnt inhibitor-induced TTFs using the
ReliaPrep RNA Cell Miniprep System (Promega, Z6012). The RNA quality was
determined by the RNA Integrity Number (RIN) value with an RNA6000 assay
(Agilent). Only specimens with RIN > 7.0 were used in this study. Gene expression
levels were determined by microarray (Clariom S Array, Mouse, Affymetrix)
according to the manufacturer’s instructions. Prior to analysis, all data were nor-
malized by using a Single Space Transformation and Robust Multichip Analysis
(SST-RMA) algorithm with Affymetrix Expression Console software version 1.4.
Heatmaps of differentially expressed genes (>2-fold) were generated using Gene-
Spring GX (Agilent) 14.8 software. Gene ontology (GO) analyses were performed
using Database for Annotation, Visualization, and Integrated Discovery (DAVID,
URL: http://david.abcc.ncifcrf.gov/) and p values were determined by a modiﬁed
Fisher’s exact test.
Enzyme-linked immunosorbent assay. To measure the amount of cAMP pro-
duced, postnatal TTFs were plated in 24-well plates at an initial density of 1 × 104
cells/cm2. EP3 antagonist or EP4 antagonist were added to GHMT-transduced cells
and incubated for 30 min. Cell lysates were prepared, and intracellular cAMP was
determined according to the manufacturer’s instructions using the cyclic AMP
ELISA kit (Cayman, 581001).
Statistical analyses. Based on published experiments and our experience, data are
assumed to be normally distributed. Differences between groups were examined for
statistical signiﬁcance using Student’s t-tests or one-way or two-way analyses of
variance (ANOVA) followed by Dunnett’s or Tukey’s post hoc test. Differences
with P-values of <0.05 were regarded as signiﬁcant.
Data availability
The data that support the ﬁndings of this study are available from the corresponding
author upon request. The microarray data reported in this paper has been uploaded to
GEO under accession number GSE116227. The source data underlying Fig.1c and
Supplementary Figure 3a are provided in the Supplementary Information.
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